Trispecific Antibodies Emerging in Multiple Myeloma

(MedPage Today) — Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, next-generation trispecific antibodies are yielding high response rates in heavily pretreated disease…